Research Site #2 — Merrillville, Indiana

Research Site #2 is a clinical research site located in Merrillville, Indiana, United States 46410.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Research Site #2 has participated in 2 clinical trials.

Therapeutic areas: Anemia, Non-Dialysis-Dependent Chronic Kidney Disease.

Sponsors: Akebia Therapeutics.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Merrillville

Browse all research sites in Indiana · View every site in Merrillville

• Methodist Hospital Site Number : 8400164
• Methodist Hospitals
• Methodist Hospital- Merriillville ( Site 0008)
• Methodist Hospital
• Methodist Hospital Southlake
• Methodist Hospitals Southlake
• Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0039)
• Premier Oncology Hematology Associates
• Research Site
• Suniti Medical Corporation
• Urologic Specialists of Northwest Indiana
• Indiana Medical Research Institute

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Research Site #2?

Research Site #2 has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Research Site #2 conducted?

Research Site #2 has 2 clinical trials on record. Their work covers Anemia, Non-Dialysis-Dependent Chronic Kidney Disease.

Is Research Site #2 accredited by Crixeo Clinical Trials?

Research Site #2 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Research Site #2?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.